Co-mutations in EGFR driven non-small cell lung cancer

Podobne zapisy

• Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
  od: Karachaliou, Niki, i wsp.
  Wydane: (2014)
• Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
  od: Ito, Masaoki, i wsp.
  Wydane: (2019)
• Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
  od: Gregorc, Vanesa, i wsp.
  Wydane: (2018)
• Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
  od: Bracht, Jillian Wilhelmina Paulina, i wsp.
  Wydane: (2019)
• Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
  od: Rosell, Rafael, i wsp.
  Wydane: (2018)